Literature DB >> 24048415

Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia.

D Bellanger1, V Jacquemin1, M Chopin2, G Pierron1, O A Bernard3, J Ghysdael4, M-H Stern1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24048415     DOI： 10.1038/leu.2013.271

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  13 in total

1.  Somatic STAT3 mutations in large granular lymphocytic leukemia.

Authors:  Hanna L M Koskela; Samuli Eldfors; Pekka Ellonen; Arjan J van Adrichem; Heikki Kuusanmäki; Emma I Andersson; Sonja Lagström; Michael J Clemente; Thomas Olson; Sari E Jalkanen; Muntasir Mamun Majumder; Henrikki Almusa; Henrik Edgren; Maija Lepistö; Pirkko Mattila; Kathryn Guinta; Pirjo Koistinen; Taru Kuittinen; Kati Penttinen; Alun Parsons; Jonathan Knowles; Janna Saarela; Krister Wennerberg; Olli Kallioniemi; Kimmo Porkka; Thomas P Loughran; Caroline A Heckman; Jaroslaw P Maciejewski; Satu Mustjoki
Journal:  N Engl J Med       Date:  2012-05-17       Impact factor: 91.245

2.  FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma.

Authors:  Natalina E Elliott; Susan M Cleveland; Victor Grann; John Janik; Thomas A Waldmann; Utpal P Davé
Journal:  Blood       Date:  2011-08-05       Impact factor: 22.113

3.  A complex pattern of recurrent chromosomal losses and gains in T-cell prolymphocytic leukemia.

Authors:  J Soulier; G Pierron; D Vecchione; R Garand; F Brizard; F Sigaux; M H Stern; A Aurias
Journal:  Genes Chromosomes Cancer       Date:  2001-07       Impact factor: 5.006

4.  The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.

Authors:  Jinghui Zhang; Li Ding; Linda Holmfeldt; Gang Wu; Sue L Heatley; Debbie Payne-Turner; John Easton; Xiang Chen; Jianmin Wang; Michael Rusch; Charles Lu; Shann-Ching Chen; Lei Wei; J Racquel Collins-Underwood; Jing Ma; Kathryn G Roberts; Stanley B Pounds; Anatoly Ulyanov; Jared Becksfort; Pankaj Gupta; Robert Huether; Richard W Kriwacki; Matthew Parker; Daniel J McGoldrick; David Zhao; Daniel Alford; Stephen Espy; Kiran Chand Bobba; Guangchun Song; Deqing Pei; Cheng Cheng; Stefan Roberts; Michael I Barbato; Dario Campana; Elaine Coustan-Smith; Sheila A Shurtleff; Susana C Raimondi; Maria Kleppe; Jan Cools; Kristin A Shimano; Michelle L Hermiston; Sergei Doulatov; Kolja Eppert; Elisa Laurenti; Faiyaz Notta; John E Dick; Giuseppe Basso; Stephen P Hunger; Mignon L Loh; Meenakshi Devidas; Brent Wood; Stuart Winter; Kimberley P Dunsmore; Robert S Fulton; Lucinda L Fulton; Xin Hong; Christopher C Harris; David J Dooling; Kerri Ochoa; Kimberly J Johnson; John C Obenauer; William E Evans; Ching-Hon Pui; Clayton W Naeve; Timothy J Ley; Elaine R Mardis; Richard K Wilson; James R Downing; Charles G Mullighan
Journal:  Nature       Date:  2012-01-11       Impact factor: 49.962

5.  TEL-JAK2 transgenic mice develop T-cell leukemia.

Authors:  C Carron; F Cormier; A Janin; V Lacronique; M Giovannini; M T Daniel; O Bernard; J Ghysdael
Journal:  Blood       Date:  2000-06-15       Impact factor: 22.113

6.  Array-based genomic resequencing of human leukemia.

Authors:  Y Yamashita; J Yuan; I Suetake; H Suzuki; Y Ishikawa; Y L Choi; T Ueno; M Soda; T Hamada; H Haruta; S Takada; Y Miyazaki; H Kiyoi; E Ito; T Naoe; M Tomonaga; M Toyota; S Tajima; A Iwama; H Mano
Journal:  Oncogene       Date:  2010-04-19       Impact factor: 9.867

7.  JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma.

Authors:  A Bouchekioua; L Scourzic; O de Wever; Y Zhang; P Cervera; A Aline-Fardin; T Mercher; P Gaulard; R Nyga; D Jeziorowska; L Douay; W Vainchenker; F Louache; C Gespach; E Solary; P Coppo
Journal:  Leukemia       Date:  2013-05-21       Impact factor: 11.528

8.  STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model.

Authors:  Lucile Couronné; Laurianne Scourzic; Camilla Pilati; Véronique Della Valle; Yannis Duffourd; Eric Solary; William Vainchenker; Jean-Philippe Merlio; Marie Beylot-Barry; Frederik Damm; Marc-Henri Stern; Philippe Gaulard; Laurence Lamant; Eric Delabesse; Hélène Merle-Beral; Florence Nguyen-Khac; Michaëla Fontenay; Hervé Tilly; Christian Bastard; Jessica Zucman-Rossi; Olivier A Bernard; Thomas Mercher
Journal:  Haematologica       Date:  2013-07-19       Impact factor: 9.941

Review 9.  Prolymphocytic leukaemia of B- and T-cell subtype: a state-of-the-art paper.

Authors:  M Dungarwalla; E Matutes; C E Dearden
Journal:  Eur J Haematol       Date:  2008-03-10       Impact factor: 2.997

10.  Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia.

Authors:  Elisabetta Flex; Valentina Petrangeli; Lorenzo Stella; Sabina Chiaretti; Tekla Hornakova; Laurent Knoops; Cristina Ariola; Valentina Fodale; Emmanuelle Clappier; Francesca Paoloni; Simone Martinelli; Alessandra Fragale; Massimo Sanchez; Simona Tavolaro; Monica Messina; Giovanni Cazzaniga; Andrea Camera; Giovanni Pizzolo; Assunta Tornesello; Marco Vignetti; Angela Battistini; Hélène Cavé; Bruce D Gelb; Jean-Christophe Renauld; Andrea Biondi; Stefan N Constantinescu; Robin Foà; Marco Tartaglia
Journal:  J Exp Med       Date:  2008-03-24       Impact factor: 14.307
View more
  39 in total

Review 1.  Mature T-cell leukemias: Molecular and Clinical Aspects.

Authors:  Nathanael G Bailey; Kojo S J Elenitoba-Johnson
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

2.  Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma.

Authors:  Ramona Crescenzo; Francesco Abate; Elena Lasorsa; Fabrizio Tabbo'; Marcello Gaudiano; Nicoletta Chiesa; Filomena Di Giacomo; Elisa Spaccarotella; Luigi Barbarossa; Elisabetta Ercole; Maria Todaro; Michela Boi; Andrea Acquaviva; Elisa Ficarra; Domenico Novero; Andrea Rinaldi; Thomas Tousseyn; Andreas Rosenwald; Lukas Kenner; Lorenzo Cerroni; Alexander Tzankov; Maurilio Ponzoni; Marco Paulli; Dennis Weisenburger; Wing C Chan; Javeed Iqbal; Miguel A Piris; Alberto Zamo'; Carmela Ciardullo; Davide Rossi; Gianluca Gaidano; Stefano Pileri; Enrico Tiacci; Brunangelo Falini; Leonard D Shultz; Laurence Mevellec; Jorge E Vialard; Roberto Piva; Francesco Bertoni; Raul Rabadan; Giorgio Inghirami
Journal:  Cancer Cell       Date:  2015-04-13       Impact factor: 31.743

Review 3.  HiJAKing the epigenome in leukemia and lymphoma.

Authors:  Amanda C Drennan; Lixin Rui
Journal:  Leuk Lymphoma       Date:  2017-04-12

4.  Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL.

Authors:  Sandrine Degryse; Simon Bornschein; Charles E de Bock; Emilie Leroy; Marlies Vanden Bempt; Sofie Demeyer; Kris Jacobs; Ellen Geerdens; Olga Gielen; Jean Soulier; Christine J Harrison; Stefan N Constantinescu; Jan Cools
Journal:  Blood       Date:  2017-11-29       Impact factor: 22.113

Review 5.  Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia.

Authors:  Philipp B Staber; Marco Herling; Mar Bellido; Eric D Jacobsen; Matthew S Davids; Tapan Mahendra Kadia; Andrei Shustov; Olivier Tournilhac; Emmanuel Bachy; Francesco Zaja; Kimmo Porkka; Gregor Hoermann; Ingrid Simonitsch-Klupp; Claudia Haferlach; Stefan Kubicek; Marius E Mayerhoefer; Georg Hopfinger; Ulrich Jaeger; Claire Dearden
Journal:  Blood       Date:  2019-07-10       Impact factor: 22.113

6.  JAK1 somatic mutation in a myeloproliferative neoplasm.

Authors:  Suzanne O Arulogun; Hock-Lai Choong; Debbie Taylor; Paula Ambrosoli; Graham Magor; Ian M Irving; Tee-Beng Keng; Andrew C Perkins
Journal:  Haematologica       Date:  2017-05-26       Impact factor: 9.941

Review 7.  Disorders of the JAK/STAT Pathway in T Cell Lymphoma Pathogenesis: Implications for Immunotherapy.

Authors:  Thomas A Waldmann; Jing Chen
Journal:  Annu Rev Immunol       Date:  2017-02-09       Impact factor: 28.527

8.  Germline activating TYK2 mutations in pediatric patients with two primary acute lymphoblastic leukemia occurrences.

Authors:  E Waanders; B Scheijen; M C J Jongmans; H Venselaar; S V van Reijmersdal; A H A van Dijk; A Pastorczak; R D A Weren; C E van der Schoot; M van de Vorst; E Sonneveld; N Hoogerbrugge; V H J van der Velden; B Gruhn; P M Hoogerbrugge; J J M van Dongen; A Geurts van Kessel; F N van Leeuwen; R P Kuiper
Journal:  Leukemia       Date:  2016-10-13       Impact factor: 11.528

9.  Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.

Authors:  E I Andersson; S Pützer; B Yadav; O Dufva; S Khan; L He; L Sellner; A Schrader; G Crispatzu; M Oleś; H Zhang; S Adnan-Awad; S Lagström; D Bellanger; J P Mpindi; S Eldfors; T Pemovska; P Pietarinen; A Lauhio; K Tomska; C Cuesta-Mateos; E Faber; S Koschmieder; T H Brümmendorf; S Kytölä; E-R Savolainen; T Siitonen; P Ellonen; O Kallioniemi; K Wennerberg; W Ding; M-H Stern; W Huber; S Anders; J Tang; T Aittokallio; T Zenz; M Herling; S Mustjoki
Journal:  Leukemia       Date:  2017-08-14       Impact factor: 11.528

10.  Take (STAT)5: jazzing up T-cell leukemia.

Authors:  Pierluigi Porcu; Jason Dubovsky
Journal:  Blood       Date:  2014-08-28       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.